J
Jonathan A. Fletcher
Researcher at Brigham and Women's Hospital
Publications - 426
Citations - 57627
Jonathan A. Fletcher is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: GiST & PDGFRA. The author has an hindex of 109, co-authored 413 publications receiving 53642 citations. Previous affiliations of Jonathan A. Fletcher include Albany Medical College & Oregon Health & Science University.
Papers
More filters
Journal Article
Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications.
TL;DR: It is found that IRS-1 is constitutively activated in a variety of solid tumors, including breast cancers, leiomyomas, Wilms' tumors, rhabdomyosarcomas, liposar comas,LeiomyosarComas, and adrenal cortical carcinomas, and that activated IRS- 1 may present an attractive therapeutic target.
Journal ArticleDOI
BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration.
Ricardo C.T. Aguiar,Yoshihiro Yakushijin,Samir Kharbanda,Ravi Salgia,Jonathan A. Fletcher,Margaret A. Shipp +5 more
TL;DR: Differential display was used to identify a novel gene, termed BAL (B-aggressivelymphoma), which is expressed at significantly higher levels in fatal high-risk DLB-CLs than in cured low-risk tumors, indicating that the risk-related BAL gene promotes malignant B-cell migration.
Journal ArticleDOI
Protein Kinase C θ (PKCθ) Expression and Constitutive Activation in Gastrointestinal Stromal Tumors (GISTs)
Anette Duensing,Nora E. Joseph,Fabiola Medeiros,Felicity Smith,Jason L. Hornick,Michael Heinrich,Christopher L. Corless,George D. Demetri,Christopher D.M. Fletcher,Jonathan A. Fletcher +9 more
TL;DR: The signaling intermediate protein kinase C θ (PKCθ) is a diagnostic marker in GISTs, including those that lack KIT expression and/or contain PDGFRA mutations and may serve, along with KIT/PDGFRA, as a novel therapeutic target.
Journal ArticleDOI
Targeting human gastrointestinal stromal tumor cells with a quadruplex-binding small molecule.
Mekala Gunaratnam,Stephen Swank,Shozeb Haider,Katja Galesa,Anthony P. Reszka,Monica Beltran,Francisco Cuenca,Jonathan A. Fletcher,Stephen Neidle +8 more
TL;DR: It is shown here that the naphthalene diimide derivative is a potent inducer of growth arrest in a patient-derived GIST cell line at a concentration that also results in effective inhibition of telomerase activity and almost complete suppression of KIT mRNA and KIT protein expression.
Journal ArticleDOI
Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors.
Andrey Frolov,Santiago Chahwan,Michael F. Ochs,Juan Pablo Arnoletti,Zhong Zong Pan,Olga O. Favorova,Jonathan A. Fletcher,Margaret von Mehren,Burton L. Eisenberg,Andrew K. Godwin +9 more
TL;DR: The potential value of an in vitro cell model to investigate GIST response to imatinib in vivo is emphasized, for the purpose of identifying important genetic markers of clinical response, mechanisms of drug action, and possible therapeutic targets.